NCT03013881View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

October 8, 2018

Study Completion Date

April 2, 2019

Conditions

Breast Neoplasm

Interventions

BIOLOGICAL

UB-921

150 mg/vial

BIOLOGICAL

Herceptin

440 mg/vial

Trial Locations (1)

Unknown

Prime site, Taipei

Sponsors

Lead Sponsor

United BioPharma

All Listed Sponsors

collaborator

Tri-Service General Hospital

OTHER

lead

United BioPharma

INDUSTRY